This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The pandemic has ushered in a number of major changes to healthcare systems, notably in the ways in which pharmaceuticalcompaniescommunicate, visit and engage with physicians. The threat of disease spread and other risk factors from COVID-19 have only compounded this.
Pharmaceuticalcompany Merck has announced that it is attempting to reduce levels of a cancer-causing compound which has been found in its popular type 2 diabetes drugs. The compound, known as nitrosamines or NTTP, often emerges from chemical reactions that can take place throughout the manufacturing process.
Just as the wider healthcare system continues to acclimate to a new normal, the way pharma and physicians communicate is experiencing a technological revolution. Physician access issues coupled with message delivery disconnects only compounded the problem. Inefficient communications pre-COVID.
In office/in person sales promotion, the staple of pharmaceuticalcompany activities, is simply not possible today with interactions reduced to the sporadic video or to telephone engagement. Understanding how to modify communication style is a first step.
In an era where medicine is rapidly becoming more personalized, why do pharmaceuticalcompanies still struggle to effectively engage with the very individuals they aim to serve? Additionally, the COVID-19 pandemic has intensified public scrutiny of pharmaceuticalcompanies, creating a unique opportunity to build trust with patients.
Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. It flows from every direction in torrents to create huge opportunities to address the world’s mounting health issues.
As this trend unfolds, it is vital to understand the benefits 5G brings, how it impacts healthcare communication , and how healthcare businesses can leverage it. 5G represents the 5th generation of cellular technology and is the gold standard in wireless communication today. In this article, we will explore these opportunities.
in 2029 , with a compound annual growth rate of 27.9%. In 2024 , the top 20 pharmaceuticalcompanies have already announced that they are actively researching uses for AI in R&D. In life sciences, chatbots and virtual assistants can be used by pharmaceuticalcompanies to improve communication with patients.
Life sciences companies can adopt third-party software-as-a-service (SaaS) solutions for drug discovery or build custom tools in collaboration with a cloud provider. For instance, many pharmaceuticalcompanies use cloud-based platforms for remote research and development labs, regulatory compliance, and clinical trial data management.
Understanding the polymorphism of a drug compound plays a key role in both drug substance and drug product development, because it can negatively impact the downstream stability, solubility, and bioavailability of a drug. We were tasked to develop a second-generation compound that would benefit from improved solubility.
But before pharmaceuticalcompanies can go to market with a breakthrough drug, they need to ensure safety and efficacy through clinical trials. Once the target is identified, researchers work to develop a compound that can interact with it. The need for new medical treatments and drugs has never been greater.
In July 2021, the pharmaceuticalcompany Pfizer issued a voluntary nationwide recall of Chantix (varenicline) tablets as a precautionary measure; this is due to the evidence of higher levels of nitrosamines in Chantix than what’s considered acceptable by the U.S. However, it can be quite challenging to do so. Chantix 0.5
Pharmaceuticalcompanies are putting their trust in the immense potential this new generation of medicine has for treating individuals with rare genetic diseases, which currently affect an estimated 280 million patients worldwide.
Allegedly, the inventor left the company, along with his proprietary recipe, and the product that the VSL #3 manufacturer has been making is different than the clinically tested product. Klaire Ther-Biotic – Another favorite high dose multi-strain probiotic of mine is made by Klaire Labs, and known as Ther-Biotic.
By removing the need for manual handling and reducing the risk of contamination, pharmaceutical manufacturers can produce products that meet the highest standards of quality. Automated systems offer a range of options for pharmaceuticalcompanies. ISPE Good Practice Guide on Containment for Potent Compounds 4.
Using content metrics, companies can understand how their current content is received and engaged with, which will, in turn, helps clarify the most effective and efficient ways to connect and communicate with their audience in the future, resulting in increased speed to market and effective content engagement.
Additionally, only one in 10 compounds (out of 10,000 screened and assessed at the pre-clinical stage) successfully passes clinical trial testing and regulatory approval, so one success needs to cover the cost of the other failures. The COVID-19 blueprint has shown a way forward.
link] A recent study published by My Green Lab 2 presented data from 74 biotechnology and pharmaceuticalcompanies tracking the change in scope 1, 2, and 3 carbon intensity (measured in tons of CO2 emitted vs. the company’s revenue in USD) since 2015. For pharmaceuticalcompanies, purchased goods (e.g.,
I started talking to Carter Black, RPh, my compounding pharmacist, about the symptoms I was experiencing, and he suggested that I have my adrenals tested. These signals create communication and function within nerves and muscles, as the electrolytes move in or out of cells. Berberine Berberine is an amazing, multi-faceted herb.
And we're utilizing direct to consumer genetic tests with a compounding pharmacy to custom compound, topical solutions for hair restoration. He's been in the compounding world for over a decade. Do I need to go find the individual with all this compounding experience? And so we just saw an opportunity and we took it.
In an era when the world is accelerating the development of drugs and targeted medicines using innovative technologies, pharmaceuticalcompanies still face registration hurdles for well-characterized molecules because of redundant or additional local regulatory requirements.
From alcohols to quaternary ammonium compounds, each type of agent has a unique mode of action, with varying degrees of efficacy. Antimicrobial agents can be used both as active pharmaceutical ingredient (API) and as excipients. There are many other aspects to take into consideration. Is Benzalkonium Chloride a good choice?
Meanwhile, the Indian biologics market is expected to grow to $12 billion by 2025, with a compound annual growth rate (CAGR) of 22%. As a result, some pharmaceuticalcompanies are turning to third parties. Moreover, skilled manpower is required to run these facilities. Please check your email to download the Whitepaper.
Large-molecule drugs such as biologics are particularly sensitive to foreign contamination and E&L interaction, making these issues key concerns for pharmaceuticalcompanies. In addition, packaging components are not entirely manufactured in a clean room environment, making them a potential source of exogenous contamination.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content